本项目主要是研发微纳米级气泡水在人们日常生活中的应用电器，实现减少乃至不用任何化工合成洗涤用品，仅利用日常生活用水及普通空气来对清洗物进行清洗，包括对人体、衣服、蔬菜以及锅碗瓢勺等进行自动深度洗净。 现在已经试制成功的自动洗澡机，可以改变当今中国乃至世界人民，花钱费力地用一种错误方法洗澡的机器。这在三年前是一个创意，2017年出第一代全自动洗澡样机，18年设立公司，今年我们计划开模具批量生产，完成对部分大客户的销售。现有的全自动微纳米级气泡水洗浴器，运用世界最先进的微纳米级气泡水制造技术，可以不用任何化工合成洗涤剂、自动清洗、深层净化体表死皮及汗腺毛囊深处的油脂汗垢；试制的样机性能已经成熟、稳定，可进行实际泡澡洗浴、人进入样机的浴缸里浸泡数分钟，就可做到全身皮肤深层净化。 本公司产品解决的市场痛点： 1、绿色环保：全世界人民每年花钱消费数千万吨的化工洗涤剂，是生活用水的最大最难处理的污染源，我们从源头杜绝水源化工污染； 2、省钱省力：不用花钱买香波浴液、洗衣粉、洗洁精，全自动省力（比如洗澡，打浴液香波搓洗是个体力活，老弱病残孕等需要照顾）； 3、健康美丽：生活中洗澡洗物不用任何化工洗涤剂，减少化工洗涤剂残留对身体健康的影响；保护皮肤（不搓洗，防止搓红皮肤---发红是皮肤表面毛细血管、淋巴被揉搓爆裂导致；防止拉伤真皮---皮肤老化、出老龄斑等都是搓洗时拉伤表皮下真皮所致）。 同时起到，杀菌抑菌、提升人体免疫力、净化血液、改善过敏体质；美容护肤、洗净皮肤、除角质、美白效果、补湿皮肤、增加弹力；改善皮肤病、改善皮肤过敏、改善青春痘、改善脚气、改善湿疹；并有增加体力、恢复疲劳、改善睡眠的湿泉效果等作用。微纳米级气泡水水还可以用于洗净蔬菜、水果上的残留农药。 本公司产品市场前景巨大，以老软病残孕洗澡为开始的养老院、月子中心、医院，所有的家庭、酒店等都会使用本产品，除了自动洗澡机，还可以开发自动洗头机、自动洗碗机、自动洗菜洗水果机等。已在中国申请22项专利（11项发明专利、11项实用新型专利）。这是一个数万亿的新市场。自创品牌商标---爱清宝。我们已经有泰康人寿养老公寓、719研究所的军民融合等合作。泰康人寿集团邀请我们参加的大健康产品博览会，希望成为他们高档养老院的标配。我们对未来三年的保守销售预测，要过亿元,本项目主要是研发微纳米级气泡水在人们日常生活中的应用电器，实现减少乃至不用任何化工合成洗涤用品，仅利用日常生活用水及普通空气来对清洗物进行清洗，包括对人体、衣服、蔬菜以及锅碗瓢勺等进行自动深度洗净。 现在已经试制成功的自动洗澡机，可以改变当今中国乃至世界人民，花钱费力地用一种错误方法洗澡的机器。这在三年前是一个创意，2017年出第一代全自动洗澡样机，18年设立公司，今年我们计划开模具批量生产，完成对部分大客户的销售。现有的全自动微纳米级气泡水洗浴器，运用世界最先进的微纳米级气泡水制造技术，可以不用任何化工合成洗涤剂、自动清洗、深层净化体表死皮及汗腺毛囊深处的油脂汗垢；试制的样机性能已经成熟、稳定，可进行实际泡澡洗浴、人进入样机的浴缸里浸泡数分钟，就可做到全身皮肤深层净化。 本公司产品解决的市场痛点： 1、绿色环保：全世界人民每年花钱消费数千万吨的化工洗涤剂，是生活用水的最大最难处理的污染源，我们从源头杜绝水源化工污染； 2、省钱省力：不用花钱买香波浴液、洗衣粉、洗洁精，全自动省力（比如洗澡，打浴液香波搓洗是个体力活，老弱病残孕等需要照顾）； 3、健康美丽：生活中洗澡洗物不用任何化工洗涤剂，减少化工洗涤剂残留对身体健康的影响；保护皮肤（不搓洗，防止搓红皮肤---发红是皮肤表面毛细血管、淋巴被揉搓爆裂导致；防止拉伤真皮---皮肤老化、出老龄斑等都是搓洗时拉伤表皮下真皮所致）。 同时起到，杀菌抑菌、提升人体免疫力、净化血液、改善过敏体质；美容护肤、洗净皮肤、除角质、美白效果、补湿皮肤、增加弹力；改善皮肤病、改善皮肤过敏、改善青春痘、改善脚气、改善湿疹；并有增加体力、恢复疲劳、改善睡眠的湿泉效果等作用。微纳米级气泡水水还可以用于洗净蔬菜、水果上的残留农药。 本公司产品市场前景巨大，以老软病残孕洗澡为开始的养老院、月子中心、医院，所有的家庭、酒店等都会使用本产品，除了自动洗澡机，还可以开发自动洗头机、自动洗碗机、自动洗菜洗水果机等。已在中国申请22项专利（11项发明专利、11项实用新型专利）。这是一个数万亿的新市场。自创品牌商标---爱清宝。我们已经有泰康人寿养老公寓、719研究所的军民融合等合作。泰康人寿集团邀请我们参加的大健康产品博览会，希望成为他们高档养老院的标配。我们对未来三年的保守销售预测，要过亿元

海外市場と同様に本邦ブラジリアンワックス市場は発展の一途を辿っている。然しながら、黎明期を抜けておらず、本商品が全ての消費者にアクセス出来ているとは言い難い。そこで今後最大の成長が見込まれるコンビニ市場への進出としてローソンへの導入を梃子に一気に市場創出を図り、同市場に於けるトップシェア獲得を目指す。(生活産業Gとの協業) 2. 原料コスト削減 ワックスの主要原料である合成樹脂を三菱商事ケミカル経由で納入することで、高額なマージンを抜く中間業者を排除し、原料コストを削減することで、競争力のある原料にて製品製造を行う。(化学品Gとの協業) 3. 製品輸出による収益拡大 Made In Japanワックスとして、韓国、台湾、タイから更に輸出市場を拡大することで、更なる売上増加を目指す。世界で最もワックス市場の成長率が高い東南アジア市場をターゲットとする。,海外市場と同様に本邦ブラジリアンワックス市場は発展の一途を辿っている。然しながら、黎明期を抜けておらず、本商品が全ての消費者にアクセス出来ているとは言い難い。そこで今後最大の成長が見込まれるコンビニ市場への進出としてローソンへの導入を梃子に一気に市場創出を図り、同市場に於けるトップシェア獲得を目指す。(生活産業Gとの協業) 2. 原料コスト削減 ワックスの主要原料である合成樹脂を三菱商事ケミカル経由で納入することで、高額なマージンを抜く中間業者を排除し、原料コストを削減することで、競争力のある原料にて製品製造を行う。(化学品Gとの協業) 3. 製品輸出による収益拡大 Made In Japanワックスとして、韓国、台湾、タイから更に輸出市場を拡大することで、更なる売上増加を目指す。世界で最もワックス市場の成長率が高い東南アジア市場をターゲットとする。

本项目基于氮化镓(GaN)化合物半导体的高性能光电器件（简称LED微矩阵投影显示）开发及商业化,特别是指基于上述第三代半导体材料的发光二极管(LED: Light Emitting Diode）微矩阵显示的技术开发与产业化。我们研发团队具有该技术的核心专利，并于2019年5月在国际平板显示会议SID2019展示了投影样机，获得了美国多个投资公司和下游客户的关注。,本项目基于氮化镓(GaN)化合物半导体的高性能光电器件（简称LED微矩阵投影显示）开发及商业化,特别是指基于上述第三代半导体材料的发光二极管(LED: Light Emitting Diode）微矩阵显示的技术开发与产业化。我们研发团队具有该技术的核心专利，并于2019年5月在国际平板显示会议SID2019展示了投影样机，获得了美国多个投资公司和下游客户的关注。

本项目的智能机器人开发以物联网框架下的传感器和遥感技术为基础，通过自主创新的视觉强化处理器进行非结构化高速视频数据采集和点对点多路无压缩无损耗传输。同时应用包括HADOOP和SPARK等大数据管理和分析系统并辅之以人工智能、机器学习、模糊逻辑等理论和实践，来建立数据过滤、清洗、分类、关联、预警、多组合集成和目标值强化等各种神经元系统及训练程序，形成动态化实时神经元变形网络、智能化运动制导、运动预测和避障优化轨迹模式。再经过自主开发的警报管理模块、风险管理模块、网络安全和决策系统来实现机器人在复杂变化环境中的应对决策智能化。,本项目的智能机器人开发以物联网框架下的传感器和遥感技术为基础，通过自主创新的视觉强化处理器进行非结构化高速视频数据采集和点对点多路无压缩无损耗传输。同时应用包括HADOOP和SPARK等大数据管理和分析系统并辅之以人工智能、机器学习、模糊逻辑等理论和实践，来建立数据过滤、清洗、分类、关联、预警、多组合集成和目标值强化等各种神经元系统及训练程序，形成动态化实时神经元变形网络、智能化运动制导、运动预测和避障优化轨迹模式。再经过自主开发的警报管理模块、风险管理模块、网络安全和决策系统来实现机器人在复杂变化环境中的应对决策智能化。

通过门店前端支付系统，用户信息通过人工智能云计算，将数据精准分析计算传输到乐格信科智慧运营平台（DMP数据信息处理调度平台）。从而实现用户信息自动累积形成客户消费画像，依据DMP数据计算主动向顾客推广店铺及优惠，店铺既摆脱高昂的广告宣传费用，实现更高效精准的宣传营销，提高营业额降低管理成本。由原来的顾客选餐厅，演变为按顾客喜好推荐餐厅及优惠。,通过门店前端支付系统，用户信息通过人工智能云计算，将数据精准分析计算传输到乐格信科智慧运营平台（DMP数据信息处理调度平台）。从而实现用户信息自动累积形成客户消费画像，依据DMP数据计算主动向顾客推广店铺及优惠，店铺既摆脱高昂的广告宣传费用，实现更高效精准的宣传营销，提高营业额降低管理成本。由原来的顾客选餐厅，演变为按顾客喜好推荐餐厅及优惠。

Each year in Australia, 110,000 people have a stroke or heart attack, with 30% of these being a repeat events. Cardiovascular disease (CVD), results in a total economic burden of 7.6 billion dollars annually. In China, 1 in 5, or 290 million people are affected by CVD and it is the leading cause of death (44.6%) annually. This disease burden led to 209.0 billion Yuan (US$26.1 billion) in direct costs in 2003. Cardiovascular events, such as ischemic heart disease and stroke, are projected to increase by 50% among the population between 2010 and 2030 (based on population aging and growth alone). To avoid having a heart attack, it is recommended they complete cardiac rehabilitation. The problem is that 70% of eligible participants do not due to barriers with the community based delivery model. Barriers include transport restrictions, inconvenient program scheduling and locations, long waitlists, variable content and a lack of data and performance monitoring. My Life is a digital behaviour change company that makes chronic disease rehabilitation, prevention and management accessible and engaging. Our unique digital delivery model incorporates social incentives with gamification and health education to provide patients with personalised healthcare. My Life is integrated into the healthcare system to support clinicians to track patient outcomes, individualise care and provide early intervention. Created by health professionals with proven experience in chronic disease rehabilitation and digital behaviour change programs at scale. My Life is supported by our advisory panel including Sean Young, the Executive Director of UCLA's Centre of Digital Behaviour and T im Blake, previously the Chief Information Officer of T asmania Health. We have health providers from across Australia trialling the My Life digital rehabilitation program which will inform the design and grow our future sales funnel. My Life is working with La T robe University and Swinburne University to complete clinical validation of our digital cardiac rehabilitation program. My Life is a software-as-a-service company and hospitals and cardiac rehabilitation (CR) centres as our customers. There are currently 1452 hospitals and 530 cardiac rehabilitation centres in Australia. The total Australian market is estimated at $140M annually. Our target is the 70% of people that currently do not completing cardiac rehabilitation, representing $100M annually. Our market expansion plans include China where we have actively been investigating the market which has 31,000 hospitals who do not have scale-able rehabilitation programs. The largest competitor to My Life are people not completing a cardiac rehabilitation program at all, with 70% of eligible patients unable due to the barriers of the current model. The traditional centre based model is the most prominent cardiac rehabilitation pathway but with less than 30% of people adopting this approach. New models of delivery have developed that include telehealth components such as the Coach Program or Cardihab. These programs integrate the use of digital technology to increase accessibility to information and data capture of patient outcomes but fail to provide sufficient strategies to increase engagement, adherence and accountability,Each year in Australia, 110,000 people have a stroke or heart attack, with 30% of these being a repeat events. Cardiovascular disease (CVD), results in a total economic burden of 7.6 billion dollars annually. In China, 1 in 5, or 290 million people are affected by CVD and it is the leading cause of death (44.6%) annually. This disease burden led to 209.0 billion Yuan (US$26.1 billion) in direct costs in 2003. Cardiovascular events, such as ischemic heart disease and stroke, are projected to increase by 50% among the population between 2010 and 2030 (based on population aging and growth alone). To avoid having a heart attack, it is recommended they complete cardiac rehabilitation. The problem is that 70% of eligible participants do not due to barriers with the community based delivery model. Barriers include transport restrictions, inconvenient program scheduling and locations, long waitlists, variable content and a lack of data and performance monitoring. My Life is a digital behaviour change company that makes chronic disease rehabilitation, prevention and management accessible and engaging. Our unique digital delivery model incorporates social incentives with gamification and health education to provide patients with personalised healthcare. My Life is integrated into the healthcare system to support clinicians to track patient outcomes, individualise care and provide early intervention. Created by health professionals with proven experience in chronic disease rehabilitation and digital behaviour change programs at scale. My Life is supported by our advisory panel including Sean Young, the Executive Director of UCLA's Centre of Digital Behaviour and T im Blake, previously the Chief Information Officer of T asmania Health. We have health providers from across Australia trialling the My Life digital rehabilitation program which will inform the design and grow our future sales funnel. My Life is working with La T robe University and Swinburne University to complete clinical validation of our digital cardiac rehabilitation program. My Life is a software-as-a-service company and hospitals and cardiac rehabilitation (CR) centres as our customers. There are currently 1452 hospitals and 530 cardiac rehabilitation centres in Australia. The total Australian market is estimated at $140M annually. Our target is the 70% of people that currently do not completing cardiac rehabilitation, representing $100M annually. Our market expansion plans include China where we have actively been investigating the market which has 31,000 hospitals who do not have scale-able rehabilitation programs. The largest competitor to My Life are people not completing a cardiac rehabilitation program at all, with 70% of eligible patients unable due to the barriers of the current model. The traditional centre based model is the most prominent cardiac rehabilitation pathway but with less than 30% of people adopting this approach. New models of delivery have developed that include telehealth components such as the Coach Program or Cardihab. These programs integrate the use of digital technology to increase accessibility to information and data capture of patient outcomes but fail to provide sufficient strategies to increase engagement, adherence and accountability